"The acquisition of Stanmore Implants provides Stryker with differentiated technologies designed to provide the most effective solutions for orthopaedic oncology surgeons. This addition underscores Stryker's commitment to our core joint replacement business and expands our presence in the global orthopaedic oncology market," said David Floyd, Group President, Stryker Orthopaedics.
"The combination of Stryker's commitment to orthopaedic oncology and Stanmore's novel orthopaedic oncology solutions provides a unique opportunity to impact a broader group of patients globally," said Michael Mainelli, Chief Executive Officer, Stanmore Implants.
More information could be found from Stryker website.
No comments:
Post a Comment